NCT05092516

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Cognitive Post-acute Sequelae of COVID-19 (PASC)

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Conditions

• Dysexecutive Syndrome
• Post-Acute Sequelae of COVID-19

Interventions

Type	Name	Description
DEVICE	Active tDCS	2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
DEVICE	Sham tDCS	Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.

Timeline

• Start date: 2022-06-07
• Primary completion: 2025-03-13
• Completion: 2026-06-15
• First posted: 2021-10-25
• Last updated: 2025-11-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study